Longevity & AgingFDA Approves First Generic Weekly Patch for Menopause Symptoms and Bone Protection
A once-weekly hormone therapy patch now has its first FDA-approved generic, according to the agency’s announcement. The patch combines estradiol and levonorgestrel and is approved for women with an intact uterus to treat moderate to severe menopause symptoms and prevent osteoporosis after menopause. The added progestogen helps protect the uterine lining from excessive growth associated with estrogen alone. FDA considers the generic therapeutically equivalent to Climara Pro, potentially expanding affordable treatment options, although pricing and availability were not provided. This is a generic approval, not a new trial showing longer life or slower aging. Women considering treatment should review their medical history with a clinician: contraindications include breast cancer, blood clots, liver disease, and unexplained genital bleeding. Common adverse reactions include skin irritation, vaginal bleeding, breast pain, and headache.
